Teams face growing pressure to deliver reliable data. Examine five practical criteria for evaluating eCOA solutions that support predictable timelines, cleaner data, and better experiences for patients.

See how real-time scoring and automated eligibility checks helped a global dermatology study reduce site burden, avoid manual errors, and move participants through screening with greater speed.

Consider these three aspects when choosing an electronic Clinical Outcome Assessments (eCOA) provider and preparing to set up an eCOA clinical trial.

Signant Biotech optimized technology for an emerging biopharmaceutical's Phase 2 COVID treatment trial in critically ill patients, minimizing paper data risks and streamlining consent and data management across multiple sites and solutions.

Discover how regulatory bodies worldwide, including the U.S. Food and Drug Administration and the European Medicines Agency, are now championing the shift towards eConsent adoption.

Hear from industry experts on how they successfully combined agile eConsent technology with global regulatory expertise to increase enrollment rates and reduce both site and patient burden.

Recently released FDA guidance showcases why electronic patient-reported outcomes (ePROs) are ideal for capturing the “voice” of the patient. See how ePRO eases oncology trials.

Explore the challenges pharmaceutical companies face in implementing PROs in cancer clinical trials as outlined in the FDA’s draft guidance, as well as strategies to overcome these obstacles.

Gain insight from several contributing experts for overcoming unique obstacles in rare disease research and learn how to better develop strategies.